Chemours Stock Receives $18.00 BMO Target After Q2 Loss

Chemours reported Q2 revenue of $1.591 billion and a $274 million GAAP loss. Analysts show mixed views, with BMO maintaining an $18.00 Buy target while UBS lowered its target to $16.00.